Antiplatelet therapy after drug-eluting stent implantation  by Warren, Josephine et al.
Journal of Cardiology 65 (2015) 98–104Review
Antiplatelet therapy after drug-eluting stent implantation
Josephine Warren (BMedSc), Usman Baber (MD), Roxana Mehran (MD)*
Mount Sinai Medical Center, New York, NY, USA
Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Drug-eluting stents: development and risks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Dual antiplatelet therapy: antiplatelet selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Duration of dual antiplatelet therapy: determining optimal length of therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Shorter DAPT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Extended DAPT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Future studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Tailoring therapy to speciﬁc subgroups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
DAPT and acute coronary syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
DAPT and diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
DAPT and high bleeding-risk patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
DAPT cessation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
A R T I C L E I N F O
Article history:
Received 4 September 2014
Accepted 5 September 2014
Available online 6 November 2014
Keywords:
Dual antiplatelet therapy
Drug-eluting stents
Percutaneous coronary intervention
A B S T R A C T
Dual antiplatelet therapy (DAPT), which is the combination of aspirin and a platelet P2Y12 inhibitor, is the
cornerstone of secondary prevention in ischemic heart disease requiring intracoronary stenting.
Although the efﬁcacy of DAPT in the reduction of ischemic events has been well validated, the optimal
duration, and indeed combination, of therapy is yet to be established. This area continues to attract
debate with new developments in stent design and antiplatelet agents, as well as evolving clinical skill
levels.
Presently, clinical guidelines advocate the use of DAPT for 6–12 months following drug-eluting stent
(DES) implantation, but this can vary according to clinical indication, bleeding risk, and country of
practice. Concerns have arisen that unnecessary prolongation of DAPT may be associated with increased
bleeding events, as well as cost. Whether these guidelines effectively cater to current stenting
techniques, devices, and antiplatelet agents remains to be determined. This review analyzes
contemporary issues surrounding DAPT following DES implantation, as researchers continue to seek
to strike the optimal balance between bleeding and thrombotic risk.
Although reduced DAPT durations continue to show promising results in preventing ischemic events
while also mitigating bleeding risk, ultimately the consideration of clinical presentation as well as
medical and social history is paramount to guiding the optimal duration and cessation of DAPT.
 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Dual antiplatelet therapy (DAPT), deﬁned as the combination of
aspirin and a platelet P2Y12 inhibitor, is initiated following
intracoronary stent implantation to prevent stent thrombosis
and subsequent ischemic complications [1]. DAPT is the founda-
tion of secondary prevention in ischemic heart disease requiring
stenting, but the optimal combination and duration of therapy
continue to attract debate with the development of new stent
designs and antiplatelet agents, as well as evolving clinical skill
levels. Drug-eluting stents (DES) were ﬁrst introduced over a
decade ago with the aim of preventing in-stent restenosis through
the delivery of anti-proliferative agents to inhibit early vascular
endothelialization [2]. Their superiority to traditional bare metal
stents (BMS) has been established in the prevention of in-stent
restenosis [3,4]; this advantage came with a paradoxical risk of late
stent thrombosis, more common in the earlier generation DES and
sometimes associated with premature DAPT cessation. This
resulted in a conservative extension of DAPT to mitigate these
risks. Subsequently, second-generation DES were developed to
provide earlier and more comprehensive endothelial coverage,
which has resulted in reduced late stent thrombotic events, as well
as myocardial infarction (MI) and stroke [5,6]. More recently,
polymer-free DES have been developed to eliminate other
potential causes of late stent thrombosis, although conclusive
data on these newer designs are yet to be established.
Presently, clinical guidelines advocate the use of DAPT for 6–12
months following DES implantation, but this can vary according to
clinical indication, bleeding risk, and country of practice
[1,7,8]. Concerns have arisen that unnecessary prolongation of
DAPT may be associated with increased bleeding events, as well as
cost. Whether these guidelines effectively cater to current stenting
techniques, devices, and antiplatelet agents remains to be
determined. This review will analyze contemporary issues
surrounding DAPT following DES implantation, as researchers
continue to seek to strike the optimal balance between bleeding
and thrombotic risk.
Drug-eluting stents: development and risks
The two major complications associated with stent implanta-
tion are stent thrombosis and in-stent restenosis. Stent thrombo-
sis, although uncommon, refers to the potentially fatal acute
occlusion of the treated vessel, commonly presenting as death or
MI. The risk is maximal early after stent implantation and
attenuates as endothelialization occurs [9]. As DES are designed
to delay endothelialization, there is a risk of late (12 months) and
very late (>12 months) stent thrombosis, more commonly seen in
the ﬁrst-generation DES which were very potent inhibitors of re-
endothelialization. This risk is further compounded by other
mechanisms that are less well understood, such as polymer
hypersensitivity [10]. It is the risk of stent thrombosis that is the
driving argument behind prolonged DAPT. In-stent restenosis is
the gradual re-occlusion of the stented segment, generally
occurring 3–12 months after stent implantation due to arterial
damage and excessive neointimal tissue proliferation [11]. In
contrast to stent thrombosis, in-stent restenosis usually presents
with less acute manifestations rendering this complication less
morbid [12]. Although the incidence of in-stent restenosis has been
greatly reduced by DES [13], the risk is not negligible, which must
be considered as DES become more and more widely used.
The ﬁrst-generation DES, which contained either sirolimus or
paclitaxel, ﬁrst received approval by the US Food and Drug
Administration over the years 2003–4. These antiproliferative
agents prevent in-stent restenosis and associated target lesion
revascularization by preventing neointimal hyperplasia. Therecommended minimum duration of DAPT was set at 3 and
6 months for sirolimus- and paclitaxel-eluting stents respectively
based on randomized controlled trial data [10]. However, the
initial enthusiasm heralding the release of the ﬁrst-generation DES
was tempered considerably by the unexpectedly high rates of late
and very late stent thrombosis seen in these patients [14]. Subse-
quently, the extension of therapy to a minimum of 12 months was
mandated [14], which remained the recommended standard of care
with the introduction of second-generation DES ﬁve years later.
However, the data informing the use of 12-month DAPT originated
from trials using ﬁrst-generation DES and therefore may over-
estimate the risk of adverse events in newer stent platforms, which
have demonstrable superiority in terms of safety and efﬁcacy
[15]. Indeed, besides the added cost associated with prolongation of
DAPT, there is also concern regarding the increased risk of major
bleeding, which correlates with length of therapy [16,17].
Dual antiplatelet therapy: antiplatelet selection
The role of aspirin in the secondary prevention of thrombotic
events following DES implantation has been well established
[18,19]. Although most of the large-scale trials are based on data
using clopidogrel as the adjunctive antiplatelet agent, newer and
more potent agents such as ticagrelor and prasugrel are generating
increasing attention as they continue to display promising
antithrombotic potential. Both ticagrelor and prasugrel have been
integrated into the current American College of Cardiology
Foundation/American Heart Association/Society of Cardiovascular
Angiography and Interventions (ACCF/AHA/SCAI) clinical guide-
lines for use following acute coronary syndromes (ACS).
The efﬁcacy of clopidogrel, an irreversible P2Y12 inhibitor, is
also well recognized [20,21]. However, the variability in patient
responsiveness [22], as well as its low bioavailability and relative
slow onset of action, has led to the call for development of
alternative adjuncts.
Prasugrel is also a thienopyridine that inhibits platelet
aggregation, but does so with less variability. In terms of
antithrombotic potential, it was shown in the TRITON-TIMI 38 trial
[23] to be superior to clopidogrel in reducing stent thrombosis.
Although the reduction was realized at the cost of increased
bleeding risk, it did not translate to mortality differences. Increased
risk of bleeding was most marked in patients 75 years, <60 kg,
and those with a history of stroke or transient ischemic attack
(TIA), resulting in its contraindication in this patient subset
[1]. Regardless, post hoc analysis demonstrated a net clinical
beneﬁt, and a sub-analysis indicated that beneﬁt was most
signiﬁcant in the diabetic population [24].
Ticagrelor is a reversible inhibitor of platelet aggregation, which
also demonstrated superiority for reducing composite thrombotic
end-points compared to clopidogrel in the PLATO trial [25]. Signiﬁ-
cantly, ticagrelor did not increase bleeding, a ﬁnding which
persisted regardless of stent selection. Landmark analysis showed
an early beneﬁt from ticagrelor over the ﬁrst 30 days following
stent implantation, which indicates that it may be a viable
substitute for clopidogrel over shorter durations.
Guidelines indicate that ticagrelor and prasugrel are viable
alternatives to clopidogrel in the setting of ACS for the duration of
one year. However, there are currently no published randomized
studies comparing durations of DAPT following DES that integrate
the newer thienopyridine agents.
Duration of dual antiplatelet therapy: determining optimal
length of therapy
One of the major questions surrounding antiplatelet therapy
following DES implantation is the optimal duration of DAPT. At
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Health and Care Excellence (NICE) guidelines advocate the use
of DAPT for a minimum of 12 months [1,8]. The European Society of
Cardiology (ESC) recommends the use of DAPT for 6 months in
clinically stable patients and 12 months following stent implanta-
tion for ACS [7]. Recently, Xience stents (Abbott Vascular, Chicago,
IL, USA), a second-generation everolimus-eluting stent, received
the CE Mark of approval for a minimum of 3 months of DAPT
following implantation [26]. Ultimately, the duration of therapy
remains at the discretion of the treating physician, and as such
many trials have sought to deﬁne the safest minimum duration of
DAPT following DES.
Early data supporting the safety of shorter DAPT durations was
derived from observational studies. Schulz et al. [27] examined
6816 patients undergoing percutaneous coronary intervention
(PCI) to establish predictors of DES thrombosis. Stent thrombosis
occurred in 1.2% patients over 4 years, which was found at the
highest frequency during the ﬁrst 30 days following DES
implantation. The only signiﬁcant timeframe of DAPT cessation
signiﬁcantly associated with stent thrombosis was within the ﬁrst
6 months after insertion (p < 0.001), indicating that DAPT duration
less than 12 months was potentially viable. These ﬁndings were
further reinforced by Tada et al. using data from 6802 patients
enrolled in the CREDO registry. CREDO established that cessation
of DAPT at 4 months was not associated with an increased risk of
thrombotic events as compared to continued DAPT [17].
Shorter DAPT
Several moderately sized randomized controlled trials (RCTs)
have been conducted with the aim of demonstrating non-
inferiority of shorter DAPT duration compared to standard
12-month therapy (Table 1) [28–31].
The OPTIMIZE (Optimized Duration of Clopidogrel Therapy
Following Treatment With the Zotarolimus-Eluting Stent in Real-
World Clinical Practice) trial was a multicenter, open-label,Table 1
Summary of randomized controlled trial designs and results of shorter DAPT duration.
OPTIMIZE [28] RESET [
DAPT duration Short: 3 m
n = 1563
Long: 12 m
n = 1556
Short: 3 m
n = 1059
Presentation
ACS 996 1156
Stable angina 2123 961
Stent selection ZES (100%)b E-ZES (50
R-ZES (21
SES (16.
EES (12.
Study drug Aspirin
Clopidogrel
Aspir
Clopido
Primary end-point deﬁnition Death, MI, CVA, major
bleeding
Cardiac death, M
major ble
Event rate 6.0% vs. 5.8% 4.7% vs. 
HR (95% CI) 1.03 (0.77–1.38) N/A
p-Value 0.84 0.84
Bleeding deﬁnition BARC TIM
Event rate 0.6% vs. 0.9% 0.5% vs. 
HR (95% CI) 0.71 (0.32–1.60) N/A
p-Value 0.41 0.2
ACS, acute coronary syndrome; ZES, zotarolimus-eluting stent; E-ZES, endeavor zota
eluting stent; PES, paclitaxel-eluting stent; BMS, bare metal stent; HR, hazard ratio; CI,
stent thrombosis; TVR, target vessel revascularization; BARC, bleeding academic rese
a First-generation drug-eluting stent (DES).
b Second-generation DES.randomized clinical trial of 3119 patients who received 3- or
12-months of DAPT [28]. For inclusion, patients were required to
have either stable coronary artery disease or low-risk ACS, thus
reducing the correlation with real-world and high-risk settings. All
patients were treated with zotarolimus-eluting stents (ZES). The
trial indicated no increase in adverse outcomes as deﬁned by the
composite of all-cause death, MI, emergent coronary bypass,
stroke, and major bleeding between 3- and 12-month duration
therapy (6.0% vs. 5.8%, risk difference 0.17, CI 1.52 to 1.86,
p = 0.002 for non-inferiority). Importantly, landmark analysis
performed between 3 and 12 months showed comparable rates
of adverse events.
These ﬁndings were consistent with those of the RESET (REal
Safety and Efﬁcacy of 3-month dual antiplatelet Therapy following
Endeavor zotarolimus-eluting stent implantation) study, which
randomized 2117 patients to 3-month DAPT with ZES vs. 12-
month DAPT with all other DES [31]. The primary end-point of
cardiovascular death, MI, stent thrombosis (ST), target vessel
revascularization (TVR), or bleeding did not differ between groups
(4.7% vs. 4.7%, p < 0.0001 for non-inferiority), and individually the
end-points did not differ signiﬁcantly. However, the lack of
uniformity between stent selection limits direct comparison
between groups, as patients receiving shorter DAPT exclusively
received ZES.
The EXCELLENT (Efﬁcacy of Xience/Promus Versus Cypher to
Reduce Late Loss After Stenting) trial, another open-label,
randomized trial, prospectively enrolled 1443 patients to receive
either 6- or 12-month DAPT [30]. The investigators demonstrated
non-inferiority in 6-month vs. 12-month DAPT duration for the
primary end-point of target vessel failure (TVF), as deﬁned by a
composite of cardiac death, MI or TVR (4.8% vs. 4.3%, p = 0.001 for
non-inferiority). Landmark analysis at 6 months also showed
comparable event rates [hazard ratio (HR) 1.06, 95% conﬁdence
interval (CI) 0.56–2.03, p = 0.85]. However, this trial included ﬁrst-
and second-generation DES, which may confound the results and
no longer reﬂects current clinical practice.31] EXCELLENT [30] PRODIGY [29]
Long: 12 m
n = 1058
Short: 6 m
n = 722
Long: 12 m
n = 721
Short: 6 m
n = 737
Long: 24 m
n = 741
 744 1085
 699 392
.0%)b
.1%)b
1%)a
8%)b
SES (25.2%)a
EES (74.8%)b
PES (24.9%)a
ZES (25.0%)b
EES (25.1%)b
BMS (25.0%)
in
grel
Aspirin
Clopidogrel
Aspirin
Clopidogrel
I, ST, TVR or
eding
Death, MI or TVR Death, MI, CVA or ST
4.7% 4.8% v. 4.3% 10.0% vs. 10.1%
 1.14 (0.70–1.86) 0.98 (0.74–1.29)
 0.60 0.91
I TIMI TIMI
1.0% 0.3% vs. 0.6% 0.6% vs. 1.6%
 0.50 (0.09–2.73) 0.38 (0.15–0.97)
 0.42 0.04
rolimus-eluting stent; R-ZES, resolute zotarolimus-eluting stent; SES, sirolimus-
 conﬁdence interval; MI, myocardial infarction; CVA, cerebrovascular accident; ST,
arch consortium; TIMI, thrombolysis in myocardial infarction.
Cassese  et al. (2012)( 33): 6 mo nth vs. >12 mo nth DAPT 
El-Hayek et al. (2014) (32):  3-6 month  vs. >1 2 month DAPT   
DAPT      Favors longFavors short DAPT 
Death 
Myocardial infarcon 
Stent th rombosis 
Stroke 
Major bleeding  
0.36 (0.65-1.18) 0.87  
0.77 (0.74-1.52) 1.05 
0.73 (0.55-2.33) 1.14 
0.1 (0.40-1.09) 0.66 
0.0006 (0.19-0.76)  0.38 
p-value 95% CI   OR Outcome 
1010.1
1010.1
DAPT      Favors longFavors short DAPT 
Death 
Myoc ard ial infarc on 
Stent thrombosis 
Stroke 
Major blee ding  
0.47 (0.61-1.25) 0.88  
0.35 (0.85-1.57) 1.16 
0.35 (0.76-2.21) 1.29 
0.26 (0.41-1.27) 0.72 
0.01 (0.21-0.81)  0.41 
p-value 95% CI OROutcome 
Fig. 1. Odds ratios from meta-analyses [33]. DAPT, dual antiplatelet therapy; OR
odds ratio; CI, conﬁdence interval.
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After Grading Stent-Induced Intimal Hyperplasia) trial compared
6- vs. 24-month DAPT in 2013 patients. The composite end-point
(death, MI, and stroke) did not differ signiﬁcantly between
treatment groups [29]. Moreover, bleeding events were signiﬁ-
cantly reduced with shorter vs. longer DAPT duration, a ﬁnding
which was consistent across all bleeding scores (thrombolysis
in myocardial infarction bleeding risk 0.6% vs. 1.6%, HR 0.38, CI
0.15–0.97, p = 0.04). Interestingly, a sub-analysis of these data
examining effects of DAPT duration by stent type found that the
rate of primary end-point was signiﬁcantly higher in patients who
received a ZES with 24-month vs. 6-month therapy (HR 2.95, 95%
CI 1.49–5.45, p = 0.0018), suggesting that second-generation DES
beneﬁt speciﬁcally from shorter DAPT. In contrast, in the subset of
patients receiving paclitaxel-eluting stents, a ﬁrst-generation DES,
6-month therapy was associated with increased risk of thrombotic
events according to landmark analysis performed at 6–24 months.
However, these ﬁndings are considerably limited by their small
sample size and low power for demonstrating signiﬁcant
differences, but nonetheless the potential for tailoring therapy
by stent type presents an interesting area for further research.
Several meta-analyses have been conducted using data from
RCTs with the aim of providing higher statistical power to address
this contentious clinical issue. Recently, El-Hayek et al. [32]
compared short- (3–6 months, mean 4 months) and longer-term
(12–24 months, mean 14 months) DAPT following DES implanta-
tion, again conﬁrming no signiﬁcant difference in the rate of
adverse cardiovascular events (composite of MI and cardiac death)
between short- and long-term therapy (3.3% vs. 3.0%, odds ratio
(OR) 1.11, CI 0.87–1.43, p = 0.41) [32]. Using data from four RCTs
with a total of 8157 patients, the group also found that shorter
durations were associated with a signiﬁcantly lower risk of major
bleeding compared to longer therapy (0.29% vs. 0.71%, OR 0.41, CI
0.21–0.91, p = 0.01). This ﬁnding was consistent with a meta-
analysis performed by Cassese et al. [33], which found an increased
risk of major bleeding associated with >12 month vs. 6 month
DAPT (OR 2.64, 95% CI 1.31–5.30, p = 0.006). The ﬁndings from
these analyses in terms of individual ischemic and bleeding end-
points are shown in Fig. 1.
In addition, landmark analysis was performed from the point of
DAPT cessation in the shorter therapy group, revealing that while
there was no increased risk of the primary end-point, there was a
numerically higher rate of stent thrombosis (0.35% vs. 0.2%,
p = 0.22) albeit not to signiﬁcance. However, the data were not
analyzed at patient level, thus preventing adjustment to mitigate
potential confounding factors. Furthermore, there was no uniform
deﬁnition of end-points, such as bleeding, or means of adjudicating
adverse events.
The limitations of these trials have been individually addressed,
but broadly all trials were not sufﬁciently powered to demonstrate
a reduction in individual end-points, particularly in stent
thrombosis event rates when the overall incidence is already
low. They were also limited by their non-inferiority trial design for
demonstrating improved efﬁcacy or safety. There was also a lack of
uniformity in stent selection which limited the validity of direct
comparisons drawn between treatment groups. Most trials
employed stringent exclusion criteria, eliminating patients who
were clinically unstable or complex due to co-morbidities or
presenting pathology. This limits the external validity of these
data as they do not reﬂect outcomes in an all-comers population.
Finally, with the advent of newer and more potent antithrom-
botic agents such as ticagrelor and prasugrel, there is potential
for improved outcomes with shorter durations of DAPT.
However, this area requires further study as the aforementioned
studies were performed almost exclusively using aspirin and
clopidogrel.Extended DAPT
The REAL-LATE and ZEST-LATE studies examined 12- vs.
24-month DAPT to clarify the safety and efﬁcacy of extending
DAPT beyond 12 months [34]. Patients who were adverse-event
free at 12 months post-PCI insertion were eligible for inclusion in
an effort to reﬂect the common clinical scenario of deciding
whether to continue a stable patient on DAPT after 12 months
post-PCI. A total of 2701 patients were randomized to receive
either aspirin monotherapy or DAPT for a further 12 months. The
results from the merged trials indicated that there was no beneﬁt
to extending clopidogrel therapy beyond 12 months for the
composite end-point of cardiac death or MI (1.8% in the 24-month
group vs. 1.2% in the aspirin-alone group, HR 1.65, p = 0.17).
Indeed, composite event rates were numerically, albeit not
signiﬁcantly, higher in patients receiving 24 months of DAPT. Of
interest, despite recent data indicating that prolonged DAPT
increases the risk of bleeding, the investigators found no
incremental hazard of bleeding end-points in the 24-month
therapy group (1.1% vs. 1.4%, HR 0.71, CI 0.42–1.20, p = 0.20). A
major limitation of this study was that it almost exclusively
examined subjects who received ﬁrst-generation DES, which
signiﬁcantly reduces the applicability to the current second-
generation DES, highlighting the need for further study in this area
with the most up-to-date stent designs.
The DES LATE trial, an extension of the aforementioned trial,
randomly assigned 5045 patients to DAPT or aspirin monotherapy
at 12 months post-procedure in adverse event-free patients. The
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MI, and stroke did not differ between short- and long-therapy
groups at 48-month follow-up (3.2% vs. 3.8%, HR 0.84, CI 0.62–1.14,
p = 0.26) [35]. However, the rate of major bleeding was signiﬁ-
cantly lower in patients on shorter DAPT (HR 0.67, CI 0.47–0.95,
p = 0.026). Of note, patients assigned to 24-month DAPT had an
adherence rate of just 80%, which may confound the results.
Future studies
Currently, there are three large-scale randomized controlled
trials concerning optimal DAPT duration that are approaching
completion. The ﬁrst, the Dual Antiplatelet Therapy (DAPT) study
(ClinicalTrials.gov Identiﬁer: NCT00977938), is a double-blind
randomized-controlled trial enrolling 26,000+ patients to compare
12- vs. 30-month DAPT in terms of the composite end-point of
death, MI, and stroke, as well as stent thrombosis and bleeding
[36]. At 12 months post-PCI with either BMS or DES, patients will
be randomized to clopidogrel, prasugrel, or placebo, in addition to
aspirin, for an additional 18 months. Besides incorporating
prasugrel, this trial is also signiﬁcant in its unique potential to
demonstrate superiority in individual end-points with sufﬁcient
power due to the large number of patients enrolled.
Secondary to this is the OPTImal DUAL antiplatelet therapy
(OPTIDUAL) trial, which will enroll 1966 patients to compare 12-
month vs. 48-month DAPT (aspirin + clopidogrel) following DES
(ClinicalTrials.gov Identiﬁer: NCT00822536) [37]. The end-point
will be all-cause mortality, MI, stroke, and major bleeding. Finally,
the Safety and Efﬁcacy of Six Months Dual Antiplatelet Therapy
After Drug-Eluting Stenting (ISAR-SAFE) trial will compare
6000 patients randomized to either 6- or 12-month DAPT
following DES implantation (ClinicalTrials.gov Identiﬁer:
NCT00661206) with follow up to 9 months post-randomization
at 6 months [38]. Collectively, with their larger study cohorts,
double-blind design (of DAPT and ISAR-SAFE), and integration of
contemporary antiplatelet agents, these trials will shed more light
on optimal DAPT duration in contemporary stenting practice.
These studies are summarized in Table 2.
Tailoring therapy to speciﬁc subgroups
DAPT and acute coronary syndromes
In line with the ACCF/AHA/SCAI and ESC guidelines, patients
receiving DES uniformly require longer duration of DAPT
[1]. Currently, it is recommended that aspirin be combined with
a minimum of 12 months of clopidogrel, prasugrel, or ticagrelor.
However, several post hoc subgroup analyses have suggested
safety in discontinuing DAPT earlier in ACS. The subgroup analysisTable 2
Summary of future studies.
DAPT [36] 
Number of patients 26,000 1966
Study design Randomized, placebo-controlled, double-blind Rand
Comparison 12- vs. 30-month DAPT 12- v
Study drugs Aspirin + clopidogrel, or aspirin + prasugrel Aspir
Stent ZES
PES
EES
SES
DES (
Study end-points Death, MI, stroke
ST
Major bleeding
Death
Majo
DAPT, dual antiplatelet therapy; ZES, zotarolimus-eluting stent; SES, sirolimus-elutin
eluting stent; MI, myocardial infarction; ST, stent thrombosis.from PRODIGY trial indicated that ACS patients did not experience
an increase in adverse events on shorter therapy (HR 1.05, CI 0.79–
1.45, p-interaction 0.14) [39]. Sub-analyses from the EXCELLENT
and OPTIMIZE trials drew similar conclusions, but the group from
RESET found a trend toward increased adverse events with shorter
DAPT in ACS, although not to signiﬁcance [30,31,40]. Most
importantly, a large-scale observational study from Sweden [41]
comprising 56,440 patients determined that >3-month vs. 3-
month DAPT was associated with a lower rate of adverse cardiac
events (adjusted HR 0.84, 0.75–0.95, p = 0.004), indicating that
extended therapy should still be considered in the setting of ACS.
DAPT and diabetes
Diabetes is an independent predictor of thrombotic events
following stent implantation [42]. The mechanisms underlying this
risk are the combined effects of hyperglycemia, insulin resistance,
and free fatty acids, resulting in endothelial dysfunction with
impaired vasodilation, increased monocyte migration, neointimal
hyperplasia, and platelet reactivity [43]. As such, data from
observational studies have indicated that extended DAPT duration
decreases the risk of thrombotic events in patients with diabetes
across all stent types [44], a ﬁnding that was further clariﬁed by a
sub-analysis from the EXCELLENT trial [30]. Recent reports have
contradicted existing literature regarding the superiority of second-
generation over ﬁrst-generation DES in diabetics – particularly those
on insulin – who do not exhibit the same improved outcomes with
second-generation DES [45,46]. This emerging interaction between
stent type and outcome might constitute an argument for
differential DAPT in patients with diabetes.
DAPT and high bleeding-risk patients
At present, clinical guidelines indicate that patients at a higher
risk of bleeding should be treated with reduced DAPT duration to
mitigate the incremental bleeding risk associated with prolonged
DAPT [1]. Often, this translates to selection of BMS over DES due to
the shorter minimal DAPT duration required. High-risk patients
include the elderly (>75 years), patients on anticoagulant
medication, or prior history of TIA or stroke. The REACH registry
found that high bleeding-risk patients, i.e. those with a history of
stroke or TIA, had a greater risk of hemorrhagic stroke following
PCI, which was most pronounced in patients on DAPT (HR 5.21, CI
1.24–21.9) [47].
DAPT cessation
Premature DAPT cessation is a well-recognized predictor of stent
thrombosis. However, until recently, cessation was considered aOPTIDUAL [37] ISAR-SAFE [38]
 6000
omized, placebo controlled Randomized, double-blind, placebo-controlled
s. 48-month DAPT 6- vs. 12-month DAPT
in + clopidogrel Aspirin + clopidogrel
not speciﬁed) DES (not speciﬁed)
, MI, stroke
r bleeding
Death, MI, stroke, ST
Major bleeding
g stent; EES, everolimus-eluting stent; PES, paclitaxel-eluting stent; DES, drug-
J. Warren et al. / Journal of Cardiology 65 (2015) 98–104 103dichotomous on–off variable, without consideration of the underly-
ing clinical context. Mehran et al. demonstrated that the mode of
DAPT cessation carries additional predictive power for adverse
outcomes in the PARIS trial [48]. The major ﬁnding from this all-
comers study was that physician-guided discontinuation of DAPT
did not increase risk of major adverse cardiovascular events (MACE)
compared to those on continued DAPT, and that disruption due to
non-compliance or bleeding increased the risk of MACE (HR 1.50, CI
1.14–1.97, p = 0.004), an effect which was most pronounced in the
ﬁrst month following disruption. This is an important consideration
for physicians guiding DAPT duration recommendations.
Conclusion
Through the review of current literature, it is clear that
promising evidence exists to support shorter durations of DAPT
following DES implantation in stable patients. Extending therapy
may be associated with an increased risk of bleeding, but these
ﬁndings require conﬁrmation with larger-scaled studies. The value
of new antithrombotic agents as an alternative to clopidogrel also
requires substantiation with further studies. Consideration of
clinical presentation as well as medical and social history is
paramount to guiding the optimal duration and cessation of DAPT.
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